Comparative Pharmacology
Head-to-head clinical analysis: ANDROGEL versus DEPO TESTOSTERONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANDROGEL versus DEPO TESTOSTERONE.
ANDROGEL vs DEPO-TESTOSTERONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Androgen receptor agonist; testosterone replacement therapy to restore serum testosterone to physiologic levels.
Testosterone binds to androgen receptors, activating gene transcription that promotes development of male secondary sexual characteristics, anabolic effects, and erythropoiesis.
50 mg (5 g gel) applied topically once daily, preferably in the morning. Dose may be adjusted between 25 mg (2.5 g gel) and 100 mg (10 g gel) based on serum testosterone levels.
50-400 mg IM every 2-4 weeks
None Documented
None Documented
The terminal elimination half-life of testosterone from AndroGel is approximately 10-12 hours when applied topically, but due to continuous absorption from the skin depot, serum levels are sustained over 24 hours, allowing once-daily dosing.
The terminal elimination half-life of testosterone cypionate after intramuscular injection is approximately 8 days, allowing for dosing every 2-4 weeks.
Approximately 90% of a topical dose is excreted in urine as conjugated and unconjugated metabolites, with about 6% excreted in feces via bile; renal elimination is the primary route.
Testosterone is primarily excreted in urine as glucuronide and sulfate conjugates (90%) and in feces via bile (10%).
Category C
Category D/X
Androgen
Androgen